Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: Lupus 2012: New targets, new approaches

Meeting abstract

IRF5 expression profiling in SLE patients: new leads to a pathogenic signature?

BJ Barnes12*, RC Stone12, P Du3 and D Feng12

  • * Corresponding author: BJ Barnes

Author Affiliations

1 New Jersey Medical School, UMDNJ, Newark, NJ, USA

2 New Jersey Medical School - University Hospital Cancer Center, UMDNJ, Newark, NJ, USA

3 High Performance and Research Computing, UMDNJ, Newark, NJ, USA

For all author emails, please log on.

Arthritis Research & Therapy 2012, 14(Suppl 3):A32  doi:10.1186/ar3966


The electronic version of this article is the complete one and can be found online at: http://arthritis-research.com/content/14/S3/A32


Published:27 September 2012

© 2012 Barnes et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Meeting abstract

Joint linkage and association analysis from multiple laboratories have identified and confirmed polymorphisms in the interferon regulatory factor 5 (IRF5) gene that are statistically associated with susceptibility to systemic lupus erythematosus (SLE). IRF5 SNPs and genetic variants have been consistently replicated and shown to confer risk for or protection from the development of SLE. IRF5 expression is significantly upregulated in SLE patients and upregulation associates with IRF5-SLE risk haplotypes. IRF5 alternative splicing has also been shown to be elevated in SLE patients. Given that human IRF5 exists as multiple alternatively spliced transcripts, each with potentially distinct function(s), it is important to determine whether the IRF5 transcript profile expressed in healthy donor immune cells is different from that expressed in SLE patients. Moreover, the exact functional consequence of an IRF5-SLE risk haplotype on the profile of IRF5 transcripts expressed needs to be addressed. Using a combination of standard molecular cloning techniques and recent advances in next-generation sequencing technologies, we examined the profile of IRF5 transcripts expressed in purified immune cells of healthy donors and SLE patients. By enriching for IRF5, we obtained an unprecedented coverage depth >3,000-fold per sample. Molecular cloning was used to generate a full-length IRF5 variant transcriptome for the analysis of IRF5 transcript expression in primary immune cells of SLE patients and healthy donors. This method of analysis was compared with other methods that do not rely on the knowledge of an IRF5 transcriptome; that is, using junction counts and de novo junction discovery. Data from these studies support the overall complexity of IRF5 alternative splicing in SLE and resulted in the identification and isolation of 14 new differentially spliced IRF5 transcripts. Results from next-generation sequencing correlated with cloning and gave similar abundance rankings in SLE patients, thus supporting the use of this new technology for in-depth single gene transcript profiling. This study provides the first proof that SLE patients express an IRF5 transcript signature that is distinct from healthy donors, and that an IRF5-SLE risk haplotype defines the most abundant IRF5 transcripts expressed in SLE patients. We posit this newly defined workflow of next-generation sequencing for the rapid enrichment, identification, and quantification of differentially spliced transcripts in donor RNA samples.